Cyclerion Readies For Readouts In Sickle Cell, Other Rare, Serious Diseases This Year

Spun out from Ironwood with a $175m financing, Cyclerion added Bayer and Shire veteran Andreas Busch to its management team as Chief Innovation Officer as it awaits a trio of Phase II data readouts coming this year for its sGC stimulators.